Brand Intelligence Graph
Company Overview
About Be Biopharma
Be Biopharma uses CRISPR to engineer a patient's own B cells into continuous protein-secreting factories — a one-time treatment designed to replace lifelong enzyme replacement therapy for rare metabolic diseases. The company has raised $274 million in total financing including a $92 million Series C co-led by Nextech Invest and Bristol Myers Squibb, with ARCH Venture Partners as a continuing investor, and has an active Phase 1/2 trial (BeCoMe-9) for BE-101 in Hemophilia B.
Business Model & Competitive Advantage
B cells are uniquely suited for this approach: they naturally produce antibodies in large quantities, are long-lived in vivo, and can be engineered ex vivo without the viral vector constraints of other gene therapy approaches. By replacing the B cell's antibody-producing program with a therapeutic protein payload via CRISPR, Be Bio creates a personalized, long-duration protein delivery system that the patient's own immune architecture sustains.
Competitive Landscape 2025–2026
Bristol Myers Squibb's co-investment is the most significant commercial signal: BMS has one of the world's largest rare disease and hematology portfolios, and its investment thesis is likely rooted in the platform's potential to replace BMS's existing enzyme replacement therapy products with a one-time cure approach. Hemophilia B data from the Phase 1/2 trial in 2026 will be the first human validation of engineered B cell protein secretion durability.
Key Differentiators
Emerging Innovator
Be Biopharma is an emerging player bringing innovative solutions to the BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
ConcertAI
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates mult
DNAnexus
DNAnexus is the category-defining cloud platform for precision health data management, analysis, and collaboration. Founded in 2009 and headquartered in Mountain View, California, DNAnexus provides a
Saluda Medical
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US oper
Tempus
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder o
Schrödinger
Schrödinger was founded in 1990 by Richard Friesner and David Pearlman in New York City, building physics-based computational methods for molecular simulation. For over 30 years the company has develo
Compare Be Biopharma with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Be Biopharma? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Be Biopharma Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Be Biopharma vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →